Palonosetron vs Granisetron — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Serotonin-3 Receptor Antagonist

Palonosetron

Brand: Palonosetron

First FDA approval: 2018-03-23

Serotonin-3 Receptor Antagonist

Granisetron

Brand: Granisetron

First FDA approval: 2009-06-22

Lowest NADACAcquisition cost floor across all NDCs

—Per unit

$1.10Per unit

Average NADACAcross all dosage forms and strengths

—

$84.55Up to $668.76

Generic manufacturersActive ANDA holders — FDA Orange Book

1316 total ANDAs filed

1332 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$409092Full year

$11.1MFull year

Part D claims (CY24)Total fills, all strengths

7K2K beneficiaries

18K7K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$62Per claim, all NDCs

$633Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

—Zero PA friction

239Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

—None

5Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

NoneClear

Generic availableFDA Orange Book

Yes13 manufacturers